BCR and B-cell chronic lymphocytic leukemia: Therefore, it is likely that part of the clinical success of BCR signaling inhibitors is due the “metabolic reprogramming” that is induced by the expulsion of CLL cells from the pro-glycolytic microenvironment of the lymph nodes, along with direct inhibition of the metabolic changes induced by BCR signaling [73].